Drug intelligence / Profile preview

Pc1-d

Development stage: Preclinical
Modality: Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
Administration: Inhalation, Intravenous, Subcutaneous, Oral, Intranasal, Transdermal

Overview

Pc1-d is an amphiphilic carbohydrate-based Zinc(ii)phthalocyanine (Zn(ii)Pc) derivative being investigated for its potential in photodynamic therapy (PDT). As a photosensitizer, it is designed to generate singlet oxygen upon light activation, which then leads to the destruction of target cells. Research indicates that structural modifications, such as the replacement of oxygen with sulfur in non-peripheral positions, can enhance its photophysical properties, including a bathochromic shift in maximum absorption for deeper tissue penetration, and influence its binding affinity to human serum albumin (HSA) and photodynamic activity against human cancer melanoma cells.

Beyond the preview

Go deeper on Pc1-d.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pc1-d.

Explore the full profile